SLGL vs GDRX vs HIMS vs DERM

For growth investors, Sol-Gel Technologies Ltd.

(SLGL) is the stronger pick with 68. 0% revenue growth year-over-year, versus -29. 1% for Journey Medical Corporation (DERM). GoodRx Holdings, Inc. (GDRX) offers the better valuation at 33. 3x trailing P/E (9. 4x forward), making it the more compelling value choice. Analysts rate Sol-Gel Technologies Ltd. (SLGL) a "Buy" — based on 6 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, GoodRx Holdings, Inc.

(GDRX) is the cheapest at 33. 3x versus Hims & Hers Health, Inc. at 50. 3x. On forward P/E, GoodRx Holdings, Inc. is actually cheaper at 9. 4x.

Over the past 5 years, Hims & Hers Health, Inc.

(HIMS) delivered a total return of +137. 6%, compared to -91. 8% for GoodRx Holdings, Inc. (GDRX). Over 10 years, the gap is even starker: HIMS returned +188. 5% versus GDRX's -94. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Sol-Gel Technologies Ltd.

(SLGL) is the lower-risk stock at 0. 09β versus Hims & Hers Health, Inc. 's 2. 48β — meaning HIMS is approximately 2750% more volatile than SLGL relative to the S&P 500. On balance sheet safety, Sol-Gel Technologies Ltd. (SLGL) carries a lower debt/equity ratio of 4% versus 2% for Hims & Hers Health, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Sol-Gel Technologies Ltd.

(SLGL) is pulling ahead at 68. 0% versus -29. 1% for Journey Medical Corporation (DERM). On earnings-per-share growth, the picture is similar: GoodRx Holdings, Inc. grew EPS 104. 1% year-over-year, compared to -478. 9% for Sol-Gel Technologies Ltd.. Over a 3-year CAGR, SLGL leads at 70. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Hims & Hers Health, Inc.

(HIMS) is the more profitable company, earning 5. 5% net margin versus -31. 6% for Sol-Gel Technologies Ltd. — meaning it keeps 5. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: GDRX leads at 13. 4% versus -39. 2% for SLGL. At the gross margin level — before operating expenses — SLGL leads at 99. 4%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, GoodRx Holdings, Inc.

(GDRX) trades at 9. 4x forward P/E versus 69. 9x for Journey Medical Corporation — 60. 5x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for DERM: 135. 0% to $11. 75.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Sol-Gel Technologies Ltd.

(SLGL) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 09)). Hims & Hers Health, Inc. (HIMS) carries a higher beta of 2. 48 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (SLGL: -48. 0%, HIMS: +188. 5%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: SLGL is a small-cap high-growth stock; GDRX is a small-cap quality compounder stock; HIMS is a small-cap high-growth stock; DERM is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.